Literature DB >> 11215532

Phosphorylation of cytokeratin 8 and 18 in human vascular smooth muscle cells of atherosclerotic lesions and umbilical cord vessels.

H Bär1, F Bea, E Blessing, L Watson, P Wende, J Kreuzer, W Kübler, L Jahn.   

Abstract

Expression of cytokeratins (CK) is considered a hallmark of the state of epithelial differentiation. CK also occur in certain vascular smooth muscle cells (VSMC), inferring an association with a less differentiated phenotype. Recently, CK posttranslational modification was shown to occur in epithelial cells in stress, mitosis or apoptosis. The aim of this study was to determine potential CK phosphorylation patterns in human VSMC. Tissue samples of normal peripheral and coronary arteries, atherosclerotic lesions and umbilical cord vessels were evaluated by immunofluorescence microscopy applying antibodies specific for cytokeratins 8 and 18, specific cytokeratin phosphorylation sites, Ki-67-antigen as a proliferation marker and nick end labeling (TUNEL) to detect apoptosis. All samples contained cytokeratin-positive VSMC but diverse phosphorylation patterns. The C-terminal serine 431 of cytokeratin 8 (CK8Ser-431) was phosphorylated in the vast majority of CK-expressing VSMC of coronary artery lesions. Only a subset of these cells demonstrated phosphorylation of CK18Ser-33 or, to an even lesser extent, CK8Ser-73. DNA fragmentation occurred predominantly in samples containing cells with phosphorylated CK8Ser-431 domains. In contrast, occluded peripheral lesions exhibited little or no phosphorylation. Neonatal VSMC in umbilical cord vessels contain abundant phosphorylated CK domains, again predominantly CK8Ser-431, but also CK18Ser-33. Again, only single cells were found to be proliferating or to contain DNA fragmentation. Thus, abundant CK phosphorylation in VSMC of atherosclerotic lesions suggests a specific functional response to cell stress and a possible relation to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11215532     DOI: 10.1007/s003950170077

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  7 in total

Review 1.  Toward unraveling the complexity of simple epithelial keratins in human disease.

Authors:  M Bishr Omary; Nam-On Ku; Pavel Strnad; Shinichiro Hanada
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

2.  Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease.

Authors:  D L Mattey; P T Dawes; N B Nixon; L Goh; M J Banks; G D Kitas
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

3.  Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis.

Authors:  Sebastian Stintzing; Matthias Ocker; Andrea Hartner; Kerstin Amann; Letterio Barbera; Daniel Neureiter
Journal:  Virchows Arch       Date:  2009-06-26       Impact factor: 4.064

4.  Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study.

Authors:  Fabio F Stellari; Angelo Sala; Gaetano Donofrio; Francesca Ruscitti; Paola Caruso; Thomas M Topini; Kevin P Francis; Xiaojian Li; Chiara Carnini; Maurizio Civelli; Gino Villetti
Journal:  Pharmacol Res Perspect       Date:  2014-07-02

5.  Cytokeratin 8 in Association with sdLDL and ELISA Development.

Authors:  Mohmed Ashmaig
Journal:  N Am J Med Sci       Date:  2015-10

6.  Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach.

Authors:  Peter M Mihailovic; Wai Man Lio; Romana Herscovici; Kuang-Yuh Chyu; Juliana Yano; Xiaoning Zhao; Jianchang Zhou; Bo Zhou; Michael R Freeman; Wei Yang; Prediman K Shah; Bojan Cercek; Paul C Dimayuga
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

7.  Potential of Newborn and Adult Stem Cells for the Production of Vascular Constructs Using the Living Tissue Sheet Approach.

Authors:  Jean-Michel Bourget; Robert Gauvin; David Duchesneau; Murielle Remy; François A Auger; Lucie Germain
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.